Table 3.
Overrepresentation of biological pathways and processes
| PANTHER Pathways | Genes # | RefSeq Gene IDs | Expected # | P-value1 |
|---|---|---|---|---|
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | 9 | OPRM1, CREB1, DRD1, DRD2, GRM5, HTR1B, HTR7, HTR4, HTR2A | 0.38 | 2.5 × 10−8 |
| Dopamine receptor mediated signaling | 7 | SLC6A3, COMT, DRD1, DDC, DRD2, MAOA, TH | 0.17 | 8.1 × 10−8 |
| Adrenaline and noradrenaline biosynthesis | 5 | SLC6A3, COMT, DDC, MAOA, TH | 0.07 | 1.8 × 10−6 |
| Huntington disease | 5 | GRIN2B, JUN, FOS, BDNF, GRIN2A | 0.34 | 3.9 × 10−3 |
| Gonadotropin releasing hormone receptor | 6 | JUN, FOS, CREB1, HSPA8, DRD2, PRLR | 0.58 | 4.1 × 10−3 |
| Metabotropic glutamate receptor group I | 3 | GRIN2B, GRM5, GRIN2A | 0.06 | 6.1 × 10−3 |
| 5-Hydroxytryptamine biosynthesis | 2 | DDC, TH | 0.01 | 0.013 |
| Apoptosis signaling | 4 | JUN, FOS, CREB1, HSPA8 | 0.27 | 0.028 |
| Heterotrimeric G-protein signaling- Gq alpha and Go alpha mediated | 4 | OPRM1, DRD1, DRD2, GRM5 | 0.31 | 0.048 |
| Nicotine pharmacodynamics | 3 | DDC, DRD2, TH | 0.13 | 0.049 |
| Neurological system processes | 26 | OXTR, GRIN2B, CNTNAP2, SEMA6D, OPRM1, SLC6A3, COMT, FOS, CREB1, NR3C2, CHRNA7, DRD1, ASPM, DRD2, SLC6A4, BDNF, HTR1B, GRIN2A, ESR1, GRM5, AVPR1A, HTR4, FLNB, NCAM1, HTR7, HTR2A | 4.45 | 1.8 × 10−13 |
| Signal transduction | 29 | OXTR, GRIN2B, CNTNAP2, SEMA6D, JUN, OPRM1, SLC6A3, CREB1, STAT5B, NR3C2, CHRNA7, DRD1, ASPM, DRD2, SLC6A4, PTEN, BDNF, TH, HTR1B, GRIN2A, ESR1, GRM5, AVPR1A, HTR4, FLNB, NCAM1, PRLR, HTR7, HTR2A | 8.8 | 3.5 × 10−9 |
| Cell-cell signaling | 17 | GRIN2B, CNTNAP2, OPRM1, SLC6A3, CHRNA7, DRD1, DRD2, SLC6A4, BDNF, GRIN2A, HTR1B, FLNB, NCAM1, PRLR, HTR7, HTR4, HTR2A | 2.96 | 1.9 × 10−7 |
| Cellular processes | 32 | OXTR, GRIN2B, CNTNAP2, SEMA6D, JUN, OPRM1, SLC6A3, FOS, CREB1, STAT5B, NR3C2, CHRNA7, DRD1, ASPM, DRD2, SLC6A4, PTEN, BDNF, MAOA, TH, HTR1B, GRIN2A, ESR1, HDAC5, GRM5, AVPR1A, HTR4, FLNB, NCAM1, PRLR, HTR7, HTR2A | 13.12 | 3.1 × 10−7 |
| Cell surface receptor linked signal transduction | 18 | OXTR, GRIN2B, SEMA6D, CNTNAP2, OPRM1, CHRNA7, DRD1, DRD2, BDNF, GRIN2A, HTR1B, GRM5, AVPR1A, NCAM1, PRLR, HTR7, HTR4, HTR2A | 4.58 | 2.0 × 10−5 |
| Synaptic transmission | 11 | GRIN2B, CNTNAP2, OPRM1, SLC6A3, CHRNA7, BDNF, DRD2, SLC6A4, GRIN2A, FLNB, HTR4 | 1.55 | 4.2 × 10−5 |
| Nerve-nerve synaptic transmission | 5 | GRIN2B, CHRNA7, BDNF, DRD2, GRIN2A | 0.25 | 9.0 × 10−4 |
| G-protein coupled receptor protein signaling pathway | 11 | OXTR, OPRM1, CHRNA7, DRD1, DRD2, GRM5, AVPR1A, HTR1B, HTR7, HTR4, HTR2A | 2.14 | 9.6 × 10−3 |
| Blood circulation | 6 | OXTR, DRD2, AVPR1A, HTR1B, HTR7, HTR2A | 0.5 | 1.8 × 10−3 |
| Muscle contraction | 8 | OXTR, CHRNA7, ASPM, DRD2, AVPR1A, NCAM, FLNB, HTR4 | 1.26 | 5.1 × 10−3 |
| Apoptosis | 9 | FOS, STAT5B, BDNF, DRD2, MAOA, PTEN, HDAC5, NCAM, HTR4 | 2.22 | 0.049 |
Assessment of relative representation is compared to the entire genome, using the PANTHER Classification System (pantherdb.org).
1
P-values use Bonferroni correction for multiple testing.